– EMPhASIS Cohort 2 Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most Appropriate for Planned Phase 3 Program in Relapsing-Remitting Multiple Sclerosis, Expected to Begin in the Second Half of 2021 – – Secured Full Rights to IMU-838 with Settlement of Remaining Royalty Obligation to 4SC AG for $17.25 Million (50% in Cash and 50% in Shares of …
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838’s Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
– Preplanned Interim Analysis of 12-Week MRI Data from 10 mg IMU-838 Dose and Placebo, in Combination with Existing 30 and 45 mg Dose Data, Establishes Clear Dose-Response Relationship for IMU-838 – – Totality of Data Clearly Supports Decision that 30 mg Once Daily Dose of IMU-838 Will Now Be Targeted for Phase 3 Development in Relapsing-Remitting Multiple Sclerosis – …
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
NEW YORK, April 13, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, investor and industry conferences in April: April 17-22: 2021 Virtual American Academy of Neurology (AAN) Annual Meeting. Robert J. Fox, M.D., Staff Neurologist, Mellen Center …
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838
NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 – Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), today announced the signing of an agreement under which Immunic will settle its remaining obligation of a 4.4% royalty on net sales of …
Immunic, Inc. to Participate in Industry and Investor Conferences in March
NEW YORK, March 2, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management’s participation in the following industry and investor conferences in March: March 8-9: 2nd Annual European HealthTech CEO Forum. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will …
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
– Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021– – Reported Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis – – Announced Main Analysis of Phase 2 CALVID-1 Trial of IMU-838 Showing Evidence of Clinical Activity in Patients with Moderate COVID-19 – …
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
– Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline – – Primary Objective of Therapeutic Benefit Achieved in 27.3% of the Patients of the Per-Protocol Population at Week 24 – – Other Liver Biochemistry Parameters Remained Stable – – IMU-838’s Favorable Safety and Tolerability Profile Confirmed in …
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
– Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery and Clinical Improvement – – Primary and Key Secondary Endpoints Were Not Evaluable Due to the Very Low Rates of Serious Complications in the Population of Hospitalized Patients With Moderate COVID-19 – – High-Risk Patients and Patients Aged Over 65 …
Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25
NEW YORK, February 11, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference, on Thursday, February 25, …
Development of Innovative COVID-19 Therapies Needs Additional Public Funding to Help Patients in the Short-Term (in German Only)
Entwicklung innovativer COVID-19-Medikamente bedarf weitergehender öffentlicher Förderung, um Patienten schnell zu helfen Steigende Todeszahlen zeigen den hohen Bedarf an wirksamen Medikamenten, um COVID-19-Patienten zu versorgen und Krankenhäuser zu entlasten BEAT-COV begrüßt Bereitstellung von Fördermitteln für Medikamentenentwicklung durch das BMBF als ersten wichtigen Schritt, jedoch sind noch weitere entscheidende Bausteine in der öffentlichen Förderung und zur Erreichung des Förderziels erforderlich Um …